Method for preparing antigen determinant of aids virus

专利摘要:
Methods and compositions are provided for the cloning and expression of plasmids bearing genes encoding a novel protein derived from HTLV-III. This protein, which is called the gag/env protein and which contains antigenic determinants from both the core and envelope proteins of HTLV-III, can be purified to homogeneity and used as the basis for diagnostic tests to detect the presence of antibodies against viruses associated with AIDS or the viruses themselves in human sera and other biological fluids. The gag/env protein may also be formulated for use as a vaccine for protection against AIDS through prophylactic immunization.
公开号:SU1644720A3
申请号:SU874202330
申请日:1987-04-03
公开日:1991-04-23
发明作者:Митчел Кроул Роберт；Янг Дэру
申请人:Ф.Хоффманн-Ля Рош Унд Ко, Аг (Фирма)；
IPC主号:

专利说明:

The invention relates to biotechnology and medicine and can be used for the detection of AIDS antibodies and its viruses in human serum or other biological fluids, as well as in immunoprophylactic protection of humans against AIDS based on the use of protein.
EXAMPLE The DNA sequence encoding residues 15-512 (all but the first 14 amino terminal residues) of the gag gene is cut out from the recombinant phage clone HXB-3 and cloned to the EoColi expression plasmid pEV-vrf2 to obtain the plasmid pEV2 / gag 15-512.5
DNA sequences corresponding to amino acid residues 319-331 env are removed from the expression plasmid pEV3 / env 44-640 by seed directed mutagenesis for Q to obtain plasmid pEV3 / env 44-640 U 319-331.
The priming mutagenesis was carried out on the plasmid pEV3 / env 44-640 A 319-331 to remove nucleotides 15 encoding amino acid residues 514-524, and the plasmid pEV3 / env 44- 640 & 319-331 A 5U-524.
The restriction endonuclease fragment of the env gene from the plasmid pEV3 / env 44-20 640 U 319-331 A 514-524 encoding env residues 467-640 & 514-524, bind to the pEV2 / gag 15-512 fragment and result in a hybrid gene encoding residues gag 15-436 and residues 25 ki env 467-640 D 514-524 in the plasmid pEV2 / gag 15-436 / env 467-640 D 514-524.
At each design stage, plasmids are reproduced by transformation into E. coli strain MC1061 (pRK248c ts).
General procedure for the preparation of a recombinant vector.
Oil-scale isolation of plasmid DNA from 1 ml of a day-saturated culture is carried out according to the Bernboim method, which allows small amounts of DNA to be isolated from a bacterial colony for analytical purposes. Large amounts of plasmid DNA are obtained from 1 l of culture according to standard methods using centrifugation in cesium chloride o
For restriction endonucleases, a unit of activity is defined as the amount of enzyme required to cleave 1 µg of DNA in 60 minutes in a total reaction volume of 0.05 ml with m of restriction solutions, in addition to being cleaved by DNA, contain 100 µg / ml of bovine serum albumin and the following buffer components :
Bgl II: 100 mM NaCl, 10 mM Tris-HCl (pH 7.4), 10 mM MgCl2 and 10 mM 2-mercaptoethacol (2-10);
C1a I: 50 mM NaCl, 6 mM Tris-HCl (pH 7.9) and 6 mM MgCl2; Hinc II: idOO mM NaCl, 10 mM Tris-HCl (pH 7.4), 7 mM MgCl2 and 1 mM dithiothreitol (DTT);
Hind III: 50 mM NaCl, 50 mM Tris-HCl (pH 8) and 10 mM Hpa I: 6 mM KCl, 10 mM Tris-HCl (pH 7.4), 10 mM MgCl, H 1 mM DTT; Pst I: 100 mM NaCl, 10 mM Tris-HCl (pH 7.5) and 10 mM Puv II: 60 mM NaCl, 6 mM Tris-HCl (pH 7.5), 6 mM MgCle and 6 mM 2-U; Stu J: 100 mM NaCl, 10 mM Tris-HCl (pH 8), 10 mM MgCl2 and 6 mM 2-ME „
Binding of T4 DNA by ligaeoa is carried out at 16 ° C in a mixture containing DNA and 50 mM Tris-HCl (pH 7.8), 10 mM MgClfc, 20 mM DTT, 1 mM ATP and 50 µg / ml albumin bovine serum Activity unit T4 DNA ligases are defined as the amount required for 50% binding of Hind III fragments of lmbda DNA in 30 minutes at 16 ° C in 20 µl of the incubation mixture and a concentration of 5 DNA ends 0.12 µM (300 µg / ml) about
Purification of DNA fragments in agarose. After cleavage with restriction endonuclease, the DNA fragments to be cloned are isolated by electrophoresis in 1% agarose. After displaying with 1 μg / ml of ethidium bromide, thin layers of the gel containing the target fragments
DNA is extracted through a needle 21 times-h in 4 ml of a solution containing 10 mM Tris-HCl (pH 7.4), 1 mM EDTA and 300 mM NaCl. The resulting mixture is frozen for 3 hours at -80 ° C, thawed for 30 minutes at 37 ° C and centrifuged at 10,000 g for 30 minutes. The resulting liquid was filtered through a Millex 0.45 micron filter, concentrated to a volume of 0.25 ml and precipitated three times with sec-butanol and ethanol with 10 µg E, coli tRNA (transport RNA) as a carrier.
Cultural environment
The medium M9CA contains 10 g of Na2HP04, 3 g of KNe04, 0.5 g of NaCl and 1 g of NH4C1 per 1 l with 1 kM MgS04, 0.5% glucose and 0.5% casamino acids at pH 7.4,
Luria broth (BL) contains 5 g of bacto-yeast extract, 10 g of bacto-tryptone and 10 g of NaCl per 1 liter at pH 7.5.
Where indicated, antibiotics tetracycline and ampicillin are added to their final concentration of 15 and 50 µg / ml, respectively.
Transformation and isolation of recombinants,
The transformation of E3 coli strain MC1061 (pRK248dts) is carried out as follows.
200 ml of bacterial cells are grown at 30 ° C in BL to an O.P. value (optical density) of 0.5 - 1, after which the cells are harvested by centrifugation at 6000 g and 4 ° C for 5 minutes, suspended again in 50 ml of solution. containing 10 mM morpholinopropanesulfonic acid (MOPS, pH 7) and 10 mM RbClo The cells are harvested by centrifugation and resuspended in 30 ml of a solution containing 10 mM MOPS (pH 6.5), 50 mM CaClfc and 10 mM RbCl. After incubation for 30 min at 0 ° C, the cells are harvested, resuspended in 6 ml of 10 mM MOPS (pH 6.5) with 50 mM CaCl2, 10 mM RbCl and 15% glycerol and in 40 Eppendorf tubes (300 µl per tube) Aliquots are taken that are frozen to -80 ° C.
The transformation was performed by thawing aliquots per 100 µl of cells and incubated for 30.2 and 2 min, respectively, at 0, 37 and 0 ° C in the presence of a sample of the ligase mixture in 10 µl containing about 100 ng of DNA, and adding 0.1-0 to the tube. , 5 ml of BC, the tube is then incubated for 60 min at 22 ° C, according to
Slowly pour 200 μl of gag cells, then replace the sequential suspension in amphibillin-containing BL, and incubate for 20 hours at 30 C.
ti env to produce the final hybrid product about
;
- Cell cultivation and induction For the preparation of plasmid pEV2 /
gene expression .45 1 / 8a8 15-512 DNA sequence,
Cultures of EoColi MC1061 containing the plasmid pRK248cIts and the expression plasmid are grown in M9CA medium at
30 C to the medium log phase and then the pace; coding residues 15-512 of the gag protein are obtained from 50 μg of recombinant phage lambda of the fl HXB-3 clone containing the proviral HTLV-III gene,
The broth is raised to 42 ° C in order to inac- tive 50 NCs are subjected to cleavage in the presence of the ftP ,, repressor. After 2 hours of injection of Cla I (50 units) and Hinc II cubing at 42 ° C, cells from 1 ml of the induced culture were separated by centrifugation and resuspended.
55
(50 units) for 120 min at 37 ° C to obtain a fragment in
in a TG buffer containing 10 mM Tris-HCl (pH 7.4) and 10% glycerol, dL of an analytical preparation.
SDS-polyacrylamide gel electrophoresis and Western-Pen analysis.
1,700 p. O (base pairs). The DNA fragment was isolated by preparative agarose gel electrophoresis and resuspended in 0.1 TE buffer (1 mM Tris-HCl (pH 7.4) with 0.1 EDTA) to a final concentration of 0.03 pmol / µl
0
five
five
Induced cells suspended in Tris-glycine (TG) buffer are mixed with an equal volume of electrophoretic buffer, incubated for 5 min at 95 ° C and subjected to electrophoresis on a 12.5% polyacrylamide gel for 5 min. After electrophoresis, proteins from the gel were eluted for 6 hours at 95 V in 12.5 mM tris and 96 mM glycine with 20% methanol and 0.01% SDS, pH 7.5 per nitrocellulose membrane (O, 1 micron). A Western blot analysis is then carried out.
Seed-directed site specific mutagenesis was carried out according to the Morinaga method. The artificial oligonucleotides used in mutagenesis were synthesized by the phosphite method using an automatic synthesizer and purified by electrophoresis on a sample. lacrylamide gel „
When hybridizing colonies, the same oligonucleotide is used as an indicator for hybridization, as in the primer-directed site speci-fic mutagenesis, after labeling the 5-end with r P (ATP using polynucleotide kinase) „
Construction of plasmid pEV2 / gag 15-512.
The design of the final expression plasmid encoding the gag / env fusion protein is obtained by constructing a plasmid (pHV2 / gag 15-512) containing nucleotides encoding all but the first 14 amino acid terminal residues. Some nucleotide encoding carboxy terminal residues
gag, then replace sequential
ti env to produce the final hybrid product about
;
NK is cleaved by Cla I (50 units) and Hinc II
(50 units) for 120 min at 37 ° C to obtain a fragment in
NK is cleaved in the presence of Cla I (50 units) and Hinc II
1,700 p. O (base pairs). The DNA fragment was isolated by preparative agarose gel electrophoresis and resuspended in 0.1 TE buffer (1 mM Tris-HCl (pH 7.4) with 0.1 EDTA) to a final concentration of 0.03 pmol / µl
To obtain a gag 2 г g fragment of the expression plasmid, Her con pEV-vrf 2 was uncoupled with Cla I (5 units) and Pvu II (5 units) for 60 min at 37 ° C and by electrophoresis at 1% m agarose gel was isolated a fragment of 1700 bp containing ftP, promoter of the DNA fragment, after preliminary precipitation with ethanol, was resuspended to a final concentration of 0.03 pmol / µl.
The plasmid pEV-vrf 2 used in this construction is a derivative of the easily accessible plasmid
 pBR322 (ATCC 31344), phage lambda ft clone HXB-3 obtained using standard techniques with recombinant
DNA from the specified cell line H-9
infected with HTLV-III. Infected
The HTLV-III human cell line is H9-HTLV-IIIB and is deposited with the American Type Culture Collection under Registration No. CRL
8543 Knowledge of the HTLV-III genome sequence makes it possible to easily construct a DNA indicator. To isolate the genome from H-9 or any other lines capable of spreading the virus.
0.03 pmol of gag / Cla I-Hinc II fragment is mixed with 0.03 pmol of pEV-vr v2 / Cla I-Puv II fragment and bound using T4 DNA ligase (200 units) for 18 h at 15 ° C in a final volume of 10 µl0. The binding product is then transformed into the E. coli strain MC1061 (pRK248dts) and the transformants are selected by growing on BL agar plates with ampicillin after incubation for 18 hours at 30 ° C. Recombinant plasmid DNAs are analyzed to determine the desired size of the cleaved fragment after cleavage with Bgl II, Pst I or Hind III restrictases. The excretion products that have been analyzed by size are then selected by polyacrylamde gel electrophoresis and Western blot analysis for the presence of gag precursor.
Cultures of cells containing the plasmid pEV2 / gag 15-512 are induced at 40 ° C, and duplicate samples of the induced cells are prepared for electrophoretic analysis in polyacrylate mid gel. After electrophoresis, the gel is divided into two parts, one half

0
five
,
0
0
stained with brilliant blue Kuassi, while the other side of the gel is subjected to electric eel and Western blot analysis using antibodies to gag.
The analysis shows that the induced cells produce proteins migrating in the gel in the form of two main bands and having a molecular weight of about 56 and. The size of the complete gag protein is 15-512 approximately 56 kC. Both major proteins react with antibodies to gag. There are also a number of smaller in the number of low molecular weight proteins that react with antibodies.
Construction of plasmid pEV3 / env 44-640 & 319-331.
The expression plasmid pEV3 / env 44-640, construction by cotra from plasmids HXB-3 and pEV-vrf described by Crolem, directs the synthesis of HTLV-III env-specific 68-kD protein in E. co-Li. DNA sequences corresponding to the env 319-331 amino acid residues are removed by priming mutagenesis using an 18-mer artificial oligonucleotide having the sequence 5 GCA TTT GTT AAC ATT AGT h. Such an oligonucleotide is designed to complement env sequences in order to attach nucleotides encoding residue 318 to nucleotides encoding residue 332. As a result of combining these sequences, a new unique region of HPA I is introduced into plasmid DNA with simultaneous removal of a fragment of 39 bp. The Stu I and Hind III sites were used to form a gap for the heterodutex molecule in the plasmid pEV3 / env 44-640.
DNA from the isolated colonies, hybridized with-92 P-labeled artificial oligonucleotide, is transformed into MC1061 (pRK248dts) and analyzed for the presence of a new unique HPA in the first region.
Construction of plasmid pEV3 / env 44-640 L 319-331 L 514-524.
The second deletion within the coding env-sequences is carried out using priming mutagenesis using an artificial oligonucleotide having the sequence 5 AGA GCA GTG
containing ft ftP promoter. 0.3 μg of PEV3 / env 44-640 & 319-331 i 514- 524 DNA are subjected to restriction with 5 Pst I (10 units) and VrD II (4 units) to obtain an approximately 4 kV fragment encoding residues of env 467 - 640 D. 514-524. The resulting DNA fragments are separated in 1% agaroe and recovered. 0.03 pmol of DNA of each isolated DNA fragment is mixed and bound for 18 h at 15 ° C in the presence of T4 DNA ligase (200 units). Ligase mixture transform the MC1061 (pRK248c ts
ten
GCA GCA GGA 3. This oligonucleotide disposes the sequences encoding the residue 513 of the env protein, next to the sequences encoding the residue 525, thereby facilitating the removal of the nucleotides encoding residues 514-57.4. The removal is carried out in the plasmid by digestion with restriction sites of HPa. I and Hind III with the creation of a single network space (gap) within the env-region.
After re-transformation
DNA from positive products, ide ....... 1G
The products of transformation, which were identified with 52 P-label-15 transformation products, were selected on a oligonucleotide, analyzed on plates with EL, agar and an ampouleshread removal of 33 bp. by usingNom. Plasmid DNA is obtained from the restriction of Hpa I restriction enzymes into local colonies and analyzed for praHind III and electrophoresis in 1% agarose. Such removal is also confirmed by the establishment of a DNA sequence followed by the use of a chemical cleavage method.
Removal of U 514-524 leads to a significant increase in env expression. 25
The construction of the plasmid pEV2 / gag 15-436 / env 467-6400,514-524.
2 pEV2 / gag 15-512 is subjected to restriction with either Cla I (5 units) and Bgl II (4 units) to obtain a fragment of approximately 1300 bp encoding residues 15-436 gag, or using Pst I - (10 units ) and Cla I (5 units) to obtain a fragment of approximately 1 Kb, Met ABP Agde Non Agde Not His Agde Trp Glu Lys lie Agde Leu Agde
Pro Gly Gly Lys Lys Lys Tyr Lys Lys Lys His He Val Trp Ala
Ser Agde Glu LeuGlu Agde Phe Ala Val As Gly Leu Leu Glu
TLr Ser Glu GlySow Agde Gin lie Leu Gly Gin Leu Gin Pro Ser
Leu Gin Thr GlySer Glu Glu Leu Agde Ser Leu Tyr Aen Thr Val
Ala Thr Leu TyrCys Val His Gin Agde Lie Glu Lie Lys Asp Thr
Lys Glu Ala LeuAsp Lys Lie Glu Glu Glu Gin Asn Lys Ser Lys
Lyr, Lys Ala GinGin Ala Ala Ala Asp Thr Gly His Ser Sec Gin
Val Ser Gin AsnTyr Pro Lie Val Gin Asn He Gin Gly Gin Met
Val His Gin Alalie Ser Pro Agde Thr Leu Asn Ala Trp Val Lys
Val Val GluLys Ala Phe Ser Pro Glu Val He Pro Met Phe
Ser Ala Leu SerGlu Gly Ala Thr Pro Gin Asp Leu Asn Thr Met
Leu Asn Thr ValGly Gly His Gin Ala Ala Met Gin Met Leu Lys
Giu Thr He AsnGlu Glu Ala Ala Glu Trp Asp Agg Val His Pro
Val His Ala GlyPro He Ala Pro Gly Gin Met Agde Glu Pro Agde
Gly Ser Asp HeAla Gly Thr Thr Ser Thr Leu Gin Glu Gin He
the size of the restriction 20 fragments after cleavage with Puv II.
Eleven of the 12 isolated clones give the required Puv II DNA fragments of 3505 and 2882 bp in size. The two analyzed clones were selected for the synthesis of the gag / env fusion protein. These cell cultures are induced, cell samples are taken for electrophoretic analysis in an SDS-polyacrylamide 30 gel, electroelution and Western-blot analysis.
Selected clones synthesize a protein of the following amino acid sequence:
containing ft ftP promoter. 0.3 μg of PEV3 / env 44-640 & 319-331 and 514- 524 DNA are subjected to restriction with Pst I (10 units) and VrD II (4 units) to obtain an approximately 4 kV fragment encoding the remains of env 467- 640 D. 514-524. The resulting DNA fragments are separated in 1% agaroe and recovered. 0.03 pmol of DNA of each isolated DNA fragment is mixed and bound for 18 h at 15 ° C in the presence of T4 DNA ligase (200 units). Ligase mixture transform MS 1061 (pRK248c ts),
d ....... 1G
transformation products are selected on plates with EL, agar and ampshosh
Trp Glu Lys lie Agde Leu Agde
the magnitude of the size of the restriction fragments after cleavage with Puv II retractase.
Eleven of the 12 isolated clones give the required Puv II DNA fragments of 3505 and 2882 bp in size. The two clones tested were selected for synthesis of the gag / env fusion protein. These cell cultures are induced, cell samples are taken for electrophoretic analysis in SDS-polyacrylamide gel, electroelution and Western blot analysis.
Selected clones synthesize a protein of the following amino acid sequence:
11164472012
Gly Trp Met Thyr Thr Asn As Prodigit Pro Glitter Arg Trp He He Glyn Tyr Val Asp Arg Ply Tyr Lys Thr Lea Arg Ala Alu Glu Gin Ala Sergins Glu Thalas Ala Trp Met Thyr Glu Thr Lea Ala Asp Cys Lys Thr Met Meth Thr Ala Cys Gly Gly Gly Ala Gly Gly Pro Gly Gly Lys Alagr Gla Ala Clu Ala Glu Ala Gly Lys Glu Gly His His Thr Ala Arg Asn Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Gly Cys Thr Glu Arg Gly Lys Ala Asn Phe Le Gly Lys Arg Asp TrpArg Trg Arg Serglu Alu Tyr Lys Tyr Lys Arg Ala Trgr Ayslag Leu thr va Gin Gin Ain Arg Gan Ain Arg Le Gin Gin Gin Ain Arg Le Gin Ain Arg Ala He Gin Ain Arg He Gin Ain Arg He Gin Asp Gin Gin Leu Le Gly He Trp Gly Cys Ser Gly Lys Leu Le Cys Thr Thr Ala Val Glu Gin He Trp Asp Ala Sergly Thr Ser Phe Asn Ala Val Val Tyr His Ser
/ h
Thus, the invention of DNA of DNA that encodes an antigenic determinate to obtain a protein that has the AIDS virus, transformation
at least one antigenic de-gshazmida strain of bacteria Escherichia
cultivating, exaggerating, and carrying out the proteins gag and env of the virus, purification of the target product, about the same, HTLV-III.45,

权利要求:
Claims (1)
[1]
increase the specificity of the antigen, the claims of the invention construct a recombinant pazasmid
pEV2 / gag 15-A36 / env 467-640 D514-524,
A method for producing an antigenic detector encoding the synthesis of the gag / minant protein of the AIDS virus, including kon-,. / env, with the next amino acid
restructuring of the recombinant plasmid sequence:
i
Arg Lep Arg He Gly Lys He Arg Lea Arg He Glu Lys He Arg Lea Arg Glu Gly Lys Lys Lys Arg Glu Arg Gin Lie
1J164472014
Ala Thr Leu Thu Su Su Val His Gin Arg He Glu Lie Lys Asp Thr Lys Glu Alu Lea Asp Lys He Glu Glu Glu Ain Asp Lys Ain Ala Ala Asp Thr Gly As Hell GanAlGerGanGerGanGluGerGluGerGlyGlu Ala Thr Pro Gin Asp Alu Ain Thr Meth Alu Ain Ala Met Meth Ain Ala Alu Alu Glu Trp Ala Gly Arg Glu Pro Arg Gly Ser Asp He Ala Gly Thr Thr Ser Ser Thr Lea Gin Glu. He He Gly Trp MetAr He Gly Le Le Asn Lys He Val Arg Met Tyr Ser Pro Thr Ser He Lea Asp He Arg Gin Gly Pro Lys Glu1 Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Le Ser Arg Ala Glu Ain Pro Asp Cys Lys Thr He Leu Lys Ala Glu Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Aly Alu Asp GinArg Lys MetArl Lys Cys Phe Asyl Cys Gly Lys Glu Glys His Tr Ala Arg Asys Cys Arg Ala Pro Arg Lys Gly Cys Trp Lys Cys Gly Lys Gly His Gin Gly Lys He Ply Arg Pro Gly Gly Gly Gly Asp Meta Arg Asp Asp Trg Arg Ser A Glu Leu Tyr Lys Tyr Lys Arg Alag Ala Gly Ser Thr Methly Ala Ala Ala Ser Alagr Gin Aul Ala Ala Alagr Ain Arg Lea Gin Ala Arg He Lea Ala Val Glu Arg Tir Leu Lys Asp Glh A Ser Ser Gly Lys Le Ser Le Cys Thr Ala A Ser Serp Al Ser Lys Ser Thr thx Trp Met Glu Trp Asp Arg Glu He Asn Aen Tyr Thr Ser Phe Asn Ala Val Val Tyr His Ser
this plasmid is transformed into the strain target product and purified
E. coli ATCC P 53338, and as a fused protein ga.fje.nv.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1644720A3|1991-04-23|Method for preparing antigen determinant of aids virus

---

US5763192A|1998-06-09|Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique

---

US6569641B1|2003-05-27|Process for obtaining DNA, RNA, peptides, polypeptides, or protein by recombinant DNA technique

---

AU699732B2|1998-12-10|Compositions and methods for identifying biologically active molecules

---

Boulain et al.1986|Mutagenesis by random linker insertion into the lamB gene of Escherichia coli K12

---

US6605448B1|2003-08-12|Method and means for sorting and identifying biological information

---

EP0136489B1|1987-11-25|Analogs of human interleukin ii and their preparation

---

Saxena et al.1987|Isolation and sequencing of cDNA clones encoding alpha and beta subunits of Drosophila melanogaster casein kinase II

---

EP0540064B1|1997-10-15|Apoaequorin peptides, recombinant DNA vectors capable of expressing the same and microorganisms containing said vectors

---

JP2865283B2|1999-03-08|Recombinant viral proteins associated with lymph node disease syndrome and / or acquired immunodeficiency syndrome

---

DK174927B1|2004-03-01|DNA encoding human factor VIII: C, vector comprising this DNA, transformed host comprising this DNA, and method for producing human factor VIII: C

---

CA1341439C|2003-09-23|Feline t-lymphotropic lentivirus

---

Groarke et al.1983|The amino acid sequence of D-ribose-binding protein from Escherichia coli K12.

---

WO1990003735A1|1990-04-19|Methods and systems for producing hiv antigens

---

KR920009543B1|1992-10-19|Novel beta-urogastrone gene

---

KR960005181B1|1996-04-22|Recombinant-htlv-ñ�-protein and their usage

---

JPH07121229B2|1995-12-25|Preparation of Acid Amide-Carboxy Terminated Polypeptides

---

KR890004807B1|1989-11-27|Dna coding for antigen protein of rinderpest virus

---

Katsuya et al.1987|Construction of a new plasmid vector that can express cloned cDNA in all translational reading frames

---

JP2665338B2|1997-10-22|Methods for creating site-specific mutants

---

KR910000457B1|1991-01-25|Expression vector ptrp 322h-high for human growth hormone

---

EP0458437B1|1996-10-09|Process for production of human nerve growth factor by genetic engineering

---

JPWO2007043715A1|2009-04-23|RNA-binding peptide

---

EP0424429A1|1991-05-02|New expression vectors

---

JPH10248583A|1998-09-22|Dna polymerase and dna polymerase gene capable of coding the same

同族专利:

---

公开号 | 公开日

---

NL192275B|1996-12-02|

---

JPS62244393A|1987-10-24|

---

DE3711016A1|1987-10-08|

---

FR2606422B1|1991-01-04|

---

GB2188639B|1990-09-26|

---

GB2188639A|1987-10-07|

---

IT8719973D0|1987-04-03|

---

IT1203851B|1989-02-23|

---

IL82088A|1991-11-21|

---

ES2016426A6|1990-11-01|

---

DK166087A|1987-10-05|

---

CA1341249C|2001-06-12|

---

FR2606422A1|1988-05-13|

---

DK166087D0|1987-04-01|

---

ES2004133A6|1988-12-01|

---

NO871409L|1987-10-05|

---

SE8701413D0|1987-04-03|

---

GB8707971D0|1987-05-07|

---

NZ219837A|1990-09-26|

---

NO871409D0|1987-04-03|

---

BR8701528A|1988-01-19|

---

BE1001973A5|1990-05-02|

---

JP2625118B2|1997-07-02|

---

NL192275C|1997-04-03|

---

IL82088D0|1987-10-30|

---

AU599091B2|1990-07-12|

---

DE3744827C2|1990-08-09|

---

KR870010189A|1987-11-30|

---

ZA871724B|1987-11-25|

---

SG102792G|1993-01-29|

---

ES2009350A6|1989-09-16|

---

AU7103287A|1987-10-08|

---

DE3711016C2|1990-08-02|

---

KR930001118B1|1993-02-18|

---

AT400442B|1995-12-27|

---

SE8701413L|1987-10-05|

---

NL8700795A|1987-11-02|

---

CH676004A5|1990-11-30|

---

DK172274B1|1998-02-16|

---

US4925784A|1990-05-15|

---

ATA82487A|1995-05-15|

---

DE3744825C2|1990-10-25|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4237224A|1974-11-04|1980-12-02|Board Of Trustees Of The Leland Stanford Jr. University|Process for producing biologically functional molecular chimeras|

---

DE2814039C3|1978-03-31|1981-02-19|Gesellschaft Fuer Biotechnologische Forschung Mbh , 3300 Braunschweig|Process for the production of hybrid bacteria|

---

GB8324800D0|1983-09-15|1983-10-19|Pasteur Institut|Antigens|

---

IE58321B1|1984-04-23|1993-09-08|Us Health|Isolation of proteins of HTLV-III, serological detection of antibodies to HTLV-III in sera of patients with aids and pre-aids conditions, and detection of HTLV-III infection bi/immuno-assays using HTLV-III infection by immuno-assays using HTLV-III and its proteins|

---

WO1986000930A1|1984-07-20|1986-02-13|Worcester Foundation For Experimental Biology|Retroviral vaccines and vectors and methods for their construction|

---

IL76082A|1984-08-22|1991-07-18|Us Health|Molecular clones of the genome of htlv-iii and a process for the preparation thereof|

---

GB8423659D0|1984-09-19|1984-10-24|Pasteur Institut|Cloned dna sequences|

---

CA1340878C|1984-10-26|2000-01-25|Takis S. Papas|Production of human t-cell leukemia retrovirus envelope protein fragments in bacteria and use in seroepidemiological survey of human lymphoid malignancies|

---

CA1341423C|1984-10-31|2003-03-04|Paul A. Luciw|Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome|

---

DE3588134T2|1984-12-24|1997-03-20|Genentech Inc|Fusion of AIDS-related polypeptides|

---

US4774175A|1985-03-01|1988-09-27|Centocor, Inc.|Immunochemical methods for the detection of antibody against HTLV-III|

---

US4751180A|1985-03-28|1988-06-14|Chiron Corporation|Expression using fused genes providing for protein product|

---

DE3650011T2|1985-04-08|1994-11-17|Genetic Systems Corp|EXPRESSION AND DIAGNOSIS WITH GAG-CODED PEPTIDES THAT ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES AGAINST LAV.|

---

DK171119B1|1985-04-19|1996-06-17|Hoffmann La Roche|AIDS virus envelope protein, expression vector carrying the envelope protein, transformants transformed with the expression vector, method of producing the virus envelope protein, method of detecting AIDS antibodies, method of determining AIDS virus, vaccine against AIDS, antibodies against the virus envelope protein and use of it to prepare a vaccine and for testing|

---

WO1986006414A1|1985-04-29|1986-11-06|Genetic Systems Corporation|Synthetic antigens for the detection of aids-related disease|

---

EP0213894A3|1985-08-23|1987-10-21|Advanced Genetics Research Institute|Defective viral particle vaccines and methods for their use|

---

JP2564268B2|1985-08-28|1996-12-18|協和醗酵工業株式会社|Fusion antigen polypeptide|

---

JP2702911B2|1985-09-11|1998-01-26|ユナイテツド・バイオメデイカル・インコ−ポレ−テツド|Synthetic peptide, and method for detecting AIDS and pre-AIDS using the same|

---

IL80073D0|1985-09-25|1986-12-31|Oncogen|Vaccines and immunoassays for acquired immune deficiency syndrome|

---

GB8525615D0|1985-10-17|1985-11-20|Hoffmann La Roche|Polypeptides|

---

JPS63501716A|1985-10-24|1988-07-14|

---

AU6713287A|1986-01-06|1987-07-09|F. Hoffmann-La Roche & Co.|Expression of htlv-iii gag-gene|

---

US4753873A|1986-02-03|1988-06-28|Cambridge Bioscience Corporation|Peptides for the diagnosis of HTLV-III antibodies, their preparation and use|

---

US4734362A|1986-02-03|1988-03-29|Cambridge Bioscience Corporation|Process for purifying recombinant proteins, and products thereof|

---

US4808536A|1986-02-27|1989-02-28|Centocor, Inc.|Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein|

---

US4925784A|1986-04-04|1990-05-15|Hoffmann-La Roche Inc.|Expression and purification of an HTLV-III gag/env gene protein|

---

GB8629116D0|1986-12-05|1987-01-14|Hoffmann La Roche|Env/gag polypeptides|US9309574B1|1984-08-22|2016-04-12|The United States Of America As Represented By The Secretary, Department Of Health And Human Services|Molecular cloning of HIV-1 from immortalized cell lines|

---

AT87103T|1985-12-17|1993-04-15|Akzo Nv|IMMUNOCHEMICAL REAGENT.|

---

JPS62502868A|1985-12-24|1987-11-19|Us Commerce|

---

US4925784A|1986-04-04|1990-05-15|Hoffmann-La Roche Inc.|Expression and purification of an HTLV-III gag/env gene protein|

---

US4983387A|1986-05-19|1991-01-08|Viral Technologies Inc.|HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus|

---

US5142025A|1986-08-01|1992-08-25|Repligen Corporation|Recombinant HTLV-III proteins and uses thereof|

---

US5166050A|1986-08-20|1992-11-24|Bristol-Myers Squibb Company|Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections|

---

NZ221440A|1986-08-20|1991-11-26|Genetic Systems Corp|Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections|

---

US5041385A|1986-11-01|1991-08-20|Oxford Gene Systems Limited|Vector expressing fusion proteins and particles|

---

EP0287226A1|1987-03-23|1988-10-19|Hiver Limited|Novel vaccines|

---

NZ226026A|1987-09-04|1991-03-26|Wellcome Found|Immunoassay for an antibody using recombinant antigens expressed in two different genera|

---

EP0311228A3|1987-10-09|1990-05-02|Repligen Corporation|Recombinant polypeptides and their uses, including assay for aids virus|

---

NO881501L|1987-10-09|1989-04-10|Repligen Corp|RECOMBINANT HTLV-111 PROTEINS AND USES OF THESE.|

---

US5780038A|1987-11-16|1998-07-14|Roche Diagnostic Systems, Inc.|HIV-2 envelope polypeptides|

---

ES2054769T3|1987-11-16|1994-08-16|Hoffmann La Roche|RECOMBINANT HIV-2 POLYPEPTIDES.|

---

JPH01179687A|1987-12-30|1989-07-17|Chemo Sero Therapeut Res Inst|Hiv fused protein|

---

JP2559482B2|1988-01-12|1996-12-04|ジーンラブズテクノロジーズ，インコーポレイテッド|HTLV-I peptide antigen and assay|

---

DE68917520T2|1988-05-06|1995-01-05|Ferropas Ag|Methods and systems for producing HIV antigens.|

---

US5204259A|1988-05-06|1993-04-20|Pharmacia Genetic Engineering, Inc.|Methods and systems for producing HIV antigens|

---

FR2632310B1|1988-06-06|1992-04-10|Pasteur Institut|PEPTIDES HAVING PROTECTIVE PROPERTIES OF A PATHOGENIC VIRUS OF THE HIV TYPE IN SENSITIVE CELLS|

---

US6197496B1|1988-06-09|2001-03-06|Institut Pasteur|Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80|

---

CA2003383A1|1988-11-23|1990-05-23|Sushil G. Devare|Synthetic dna derived recombinant hiv antigens|

---

US5817318A|1989-05-03|1998-10-06|Connaught Laboratories Limited|Synthetic peptides for an HIV-1 vaccine|

---

GB8923123D0|1989-10-13|1989-11-29|Connaught Lab|A vaccine for human immunodeficiency virus|

---

DE69131513T3|1990-03-21|2005-05-25|Geneart Gmbh|DNA sequences encoding modified retroviral GAG polypeptides and vaccines or aggregates thereof containing them|

---

US6228608B1|1991-02-28|2001-05-08|Aquila Biopharmaceuticals, Inc.|Recombinant FIV glycoprotein 160 and P24 gag protein|

---

CA2116026C|1991-08-21|2004-11-23|Suresh M. Desai|Hepatitis c assay utilizing recombinant antigens to c-100 region|

---

GB9208218D0|1992-04-14|1992-05-27|British Bio Technology|Hybrid particles|

---

AT199394T|1992-06-04|2001-03-15|Univ Osaka Res Found|GAG-ENV FUSION ANTIGENS FROM HIV|

---

KR0172970B1|1992-06-17|1999-02-01|김영길|Chimeric proteins useful for an aids vaccine and the preparation thereof|

---

US5580773A|1992-06-17|1996-12-03|Korea Green Cross Corporation|Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus |

---

ES2201055T3|1992-08-07|2004-03-16|Wyeth|RECOMBINANT ADENOVIRUS VACCINES.|

---

RU2201421C2|1993-06-09|2003-03-27|Коннот Лабораториз Лимитед|Synthetic hiv peptide , immunogenic composition for induction of immune response against hiv peptides, diagnostic set for assay of hiv-specific antibodies|

---

DE69432730T2|1993-08-11|2004-03-25|Wyeth|Recombinant adenovirus vaccines|

---

US6025141A|1993-12-10|2000-02-15|The Canadian Red Cross Society|Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form|

---

DE4405810A1|1994-02-23|1995-08-24|Behringwerke Ag|Peptides derived from a retrovirus from the HIV group and their use|

---

AU2517895A|1994-05-20|1995-12-18|Microgenesys, Inc.|Hiv polyprotein immunogens|

---

FR2726576B1|1994-11-07|1997-01-31|Pf Medicament|PRODUCTION OF HYDROPHOBIC PEPTIDE-LIKE PEPTIDES, RECOMBINANT PEPTIDE, CORRESPONDING DNA SEQUENCE|

---

US6846905B2|1997-08-15|2005-01-25|Abbott Laboratories|Antigen constructs useful in the detection and differentiation of antibodies to HIV|

---

NO311807B1|1999-03-04|2002-01-28|Bionor Immuno As|HIV peptides, antigens, vaccine preparations, immunoassay test kits and a method for detecting antibodies induced by HIV|

---

DE10106295C1|2001-02-02|2002-08-22|Gaifar German American Inst Fo|Protein with multiple antigen-epitope sequences, which is immobilized|

---

CN104717974A|2012-06-06|2015-06-17|比奥诺尔免疫有限公司|Vaccine|

---

CA2951616A1|2014-07-11|2016-01-14|Bionor Immuno As|Method for reducing and/or delaying pathological effects of human immunodeficiency virus ior for reducing the risk of developing acquired immunodeficiency syndrome |

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/848,671|US4925784A|1986-04-04|1986-04-04|Expression and purification of an HTLV-III gag/env gene protein|

---